Kohl's Corporation vs State Street SPDR S&P Biotech ETF — how do they compare? Kohl's Corporation trades at $19.24 (market cap $2.10B), while State Street SPDR S&P Biotech ETF trades at $159.65. The key difference: Kohl's Corporation pays a 2.7% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Kohl's Corporation nearer its low. Which is the better fit depends on your goals.
| KSS | XBI | |
|---|---|---|
Market Cap | $2.10B | — |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $24.71 | $164.28 |
52-Week Low | $11.72 | $88.79 |
Enterprise Value | $8.20B | — |
Dividend Yield | 2.7% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Trailing returns across standard periods
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →